Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
689.7 INR | -0.39% | -0.70% | -13.70% |
01/05 | Rossari Biotech's Consolidated Profit Climbs in FIscal Q4 | MT |
30/04 | Transcript : Rossari Biotech Limited, Q4 2024 Earnings Call, Apr 30, 2024 |
Sales 2024 | 1.83TCr 22Cr | Sales 2025 * | 2.09TCr 25Cr | Capitalization | 3.81TCr 46Cr |
---|---|---|---|---|---|
Net income 2024 | 130.7Cr 1.57Cr | Net income 2025 * | 164.5Cr 1.97Cr | EV / Sales 2024 | 2.04 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.82 x |
P/E ratio 2024 |
28.7
x | P/E ratio 2025 * |
23.1
x | Employees | 500 |
Yield 2024 * |
0.44% | Yield 2025 * |
0.38% | Free-Float | 31.68% |
Latest transcript on Rossari Biotech Limited
1 day | -0.39% | ||
1 week | -0.70% | ||
1 month | -5.93% | ||
3 months | -6.84% | ||
6 months | -9.18% | ||
Current year | -13.70% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 58 | 01/97/01 | |
Edward Menezes
FOU | Founder | 63 | 01/97/01 |
Ketan Sablok
DFI | Director of Finance/CFO | - | 01/23/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 50 | 29/23/29 | |
Edward Menezes
FOU | Founder | 63 | 01/97/01 |
Founder | 58 | 01/97/01 |
Date | Price | Change | Volume |
---|---|---|---|
31/24/31 | 689.7 | -0.39% | 93,937 |
30/24/30 | 692.4 | -0.50% | 29,273 |
29/24/29 | 695.9 | -0.04% | 27,979 |
28/24/28 | 696.2 | +0.41% | 50,231 |
27/24/27 | 693.3 | -0.18% | 64,481 |
Delayed Quote NSE India S.E., May 31, 2024 at 05:13 pm IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.70% | 46Cr | |
+17.07% | 6.63TCr | |
-0.29% | 4.85TCr | |
+21.61% | 4.33TCr | |
+27.32% | 2.74TCr | |
+9.25% | 1.93TCr | |
-2.14% | 1.66TCr | |
+9.75% | 1.66TCr | |
-15.01% | 1.44TCr | |
-30.22% | 1.4TCr |
- Stock Market
- Equities
- ROSSARI Stock